Boardroom Alpha
Boardroom Alpha
DARE · Additional Proxy Materials (DEFA14A) · Filed June 1, 2026

Dare Bioscience Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
June 1, 2026
Ticker
DARE
Accession
0001493152-26-026666
Boardroom Alpha · Filing insights

Daré Bioscience engages Okapi Partners as proxy solicitor for the 2026 annual meeting; costs borne by Daré.

About Dare Bioscience Inc
Market cap
$32M
1Y TSR
−13.3%
3Y TSR
−39.9%
Board grade
C+
Sector
Healthcare
CEO
Sabrina Martucci Johnson
Last annual meeting: Jun 11, 2026 · View full Dare Bioscience Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
       
Check the appropriate box:  
       
  Preliminary Proxy Statement  
     
  Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
     
  Definitive Proxy Statement  
     
  Definitive Additional Materials  
     
  Soliciting Material under § 240.14a-12

 

DARÉ BIOSCIENCE, INC.

 

(Name of Registrant as Specified In Its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required
  Fee paid previously with preliminary materials
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

SUPPLEMENT TO PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 11, 2026

 

This proxy statement supplement (this “Supplement”), dated June 1, 2026, supplements the proxy statement filed by Daré Bioscience, Inc., a Delaware corporation (“Daré,” the “Company” and “we,” “us” or “our”), with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”) relating to the proxies being solicited by Daré’s board of directors in connection with Daré’s 2026 annual meeting of stockholders to be held on June 11, 2026 (and any adjournment or postponement thereof, the “Annual Meeting”). This Supplement should be read together with the Proxy Statement. Other than as set forth below, no changes have been made to the Proxy Statement.

 

Engagement of Proxy Solicitor

 

We engaged Okapi Partners LLC (“Okapi”), an independent proxy solicitation and advisory firm, to provide strategic advice and to assist in soliciting proxies on our behalf in connection with the Annual Meeting. Okapi may solicit proxies in person, by telephone, or by other means of communication, including by other electronic means of communication. We agreed to pay Okapi a fee of $15,000, plus additional fees and expenses, for such services. We have also agreed to indemnify Okapi against certain liabilities relating to or arising out of its engagement.

 

As stated in the Proxy Statement, we will pay for the entire cost of soliciting proxies. Our directors and employees may solicit proxies in person, by telephone, or by other means of communication. None of our directors or employees will be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks, dealers and other similar organizations for the cost of forwarding proxy materials to beneficial owners.

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Dare Bioscience Inc (DARE)

Reference

Frequently asked questions

When did Dare Bioscience Inc file this DEFA14A?
Dare Bioscience Inc (DARE) filed this Additional Proxy Materials (DEFA14A) with the SEC on June 1, 2026. The accession number assigned by EDGAR is 0001493152-26-026666.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Daré Bioscience engages Okapi Partners as proxy solicitor for the 2026 annual meeting; costs borne by Daré. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Dare Bioscience Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Dare Bioscience Inc has filed under CIK 1401914, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer